Novo Nordisk’s B shares are listed on Nasdaq Copenhagen in trading units of DKK 0.20 and its ADRs that equals B-shares of DKK 0.20 are listed on New York Stock Exchange (NYSE).
In order to secure liquidity for both the Novo Nordisk B shares and American Depositary Receipts (ADRs) and bring price levels in line with market practice for especially the ADRs, the Board of Directors has decided to split the trading units in a two-for-one ratio.
The trading unit of the Novo Nordisk B shares listed on NASDAQ Copenhagen was changed from DKK 0.20 to DKK 0.10 as of 13 September 2023. The ADRs listed on the New York Stock Exchange (NYSE) were similarly split as of 20 September 2023 to ensure that the ratio of B shares to ADRs will remain 1:1.
Novo Nordisk’s total share capital of DKK 451,000,000 is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 343,512,800.
After the split, the total number of A shares of nom. DKK 0.10 is 1,074,872,000 shares. Each A-share of nom. DKK 0,10 carries 100 votes. Consequently, the total number of votes relating to the A shares is 107,487,200,000 votes.
After the split, the total number of B shares of nom. DKK 0.10 is
3,435,128,000 shares. Each B-share of nom. DKK 0,10 carries 10 votes.
Consequently, the total number of votes relating to the B shares is